Developer of oncolytic-virus-based immunotherapies for cancer treatment. The company focuses on the development of new oncolytic virus treatments that leverage Vyriad’s vesicular stomatitis virus (VSV) platform, as well as antibody discovery capabilities. The company's lead product is Voyager-V1 which addresses multiple cancer types.
← All startups
Vyriad
Series BDeveloper of oncolytic-virus-based immunotherapies for cancer treatment. The company focuses on the development of new oncolytic virus treatments that leverage Vyriad’s vesicular stomatitis virus (VSV) platform, as well as antibody discovery capabilities. The company's lead product is Voyager-V1 which addresses multiple cancer types.
About
Institutional investors
Mayo ClinicMirae AssetRegeneron PharmaceuticalsSoutheast Minnesota Capital FundMinnesota.govRochester Area Economic DevelopmentMayo Clinic VenturesHHS
Latest coverage
📰 See all funding news — keep up with the raises that set comps.
Backed by funds in our directory
🗂️ Full list of active funds — filter by stage, check size, and geography.